UFP Technologies

Real-time Quotes | Nasdaq Last Sale

Opening 15:54 10/28 EDT
Corp Actions
At US$39.69, Is It Time To Put UFP Technologies, Inc. (NASDAQ:UFPT) On Your Watch List?
UFP Technologies, Inc. (NASDAQ:UFPT), might not be a large cap stock, but it received a lot of attention from a...
Simply Wall St. · 10/16 18:05
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of the Board, will step down as Chairman. Dr. Shapiro will remain on the Board of Directors. "I have had the honor of serving as the Chairman of VBL’s Board of Directors for many years, during a period in which the company had significant accomplishments and transitioned from R&D to late clinical stage,” said Bennett Shapiro, M.D. “I am very happy to pass the role to Marc as the next generation, and believe he is very well qualified to lead the company to fulfill its mission and bring our unique novel drug, VB-111 to cancer patients.”Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, stated, “Marc has an exceptional track record of helping biotech companies navigate to success. As VBL continues to evolve and as we get ready to provide patients in need with access to our Phase 3 anti-cancer therapy, VB-111, it is important to have Board members with the appropriate areas of expertise.  Marc brings extensive professional, strategic and financial experience, as demonstrated by his leadership roles with companies that have achieved success and significant value creation. We are confident that he will make important contributions to our company.”Marc Kozin stated, “This is an exciting time for VBL, as evidenced by the excellent progress in the ongoing OVAL trial of VB-111 in ovarian cancer, the expansion of VB-111 into new oncology indications and advancement of the pipeline. I believe that VBL is well-positioned to deliver on its mission to commercialize first-in-class treatments in cancer and immune/inflammatory indications and I look forward to contributing to the Company’s success.”Dr. Harats concluded, “I would like to thank Dr. Shapiro for his leadership and I am pleased that he will continue to serve on our Board of Directors.”Marc Kozin has three decades of industry expertise advising biopharmaceutical, life sciences and medtech companies. He is currently the Chairman of the Strategy Advisory Board of HealthCare Royalty Partners (HCR), a leading investment firm in healthcare, providing royalty monetization and senior debt. Previously, Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012. He began his career at L.E.K. in 1987 by helping establish the Boston office and led the development of L.E.K.'s industry leading life science strategic planning practice.Mr. Kozin has served on over a dozen Boards in a variety of roles and on all committees. He is currently the Lead Independent Director and serves on the Compensation Committee of UFP Technologies (Nasdaq: UFPT). He serves as Director and Chairman of the Compensation Committee for Dicerna Pharmaceuticals (Nasdaq: DRNA). Previously, he served on the board of Endocyte, helping the company negotiate a $2.1 billion M&A deal with Novartis. He was also a board member of Dyax which was acquired by Shire in 2015 for $6.5 billion.Mr. Kozin has served as Director of The Greenlight Fund, a non-profit focused on improving the lives of inner city children in families, since 2017. He was also on the Board of Governors at New England Medical Center and the Board of DukeEngage for several years. He received a BS in Economics from Duke University in 1983 and an MBA in Finance from The Wharton School in 1987.About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.Forward Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, such as the timing of clinical trials and expected announcement of data, therapeutic potential and clinical results, and our financial position and cash runway. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.INVESTOR CONTACT:Michael Rice LifeSci Advisors (646) 597-6979
GlobeNewswire · 10/13 12:00
The Returns At UFP Technologies (NASDAQ:UFPT) Provide Us With Signs Of What's To Come
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...
Simply Wall St. · 09/16 19:43
UFP Technologies Q2 EPS $0.31 Down From $0.62 YoY, Sales $42.60M Down From $51.40M YoY
UFP Technologies (NASDAQ:UFPT) reported quarterly earnings of $0.31 per share. This is a 50 percent decrease over earnings of $0.62 per share from the same period last year. The company reported $42.60 million in sales
Benzinga · 08/04 12:52
UFP Technologies Announces Q2 Results
NEWBURYPORT, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- UFP Technologies, Inc.  (Nasdaq: UFPT), an innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market, today reported net income of $2
GlobeNewswire · 08/04 12:42
Earnings Preview: UFP Technologies (UFPT) Q2 Earnings Expected to Decline
UFP (UFPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Hedge Funds Souring On UFP Technologies, Inc. (UFPT)
Insider Monkey · 06/26 16:44
UFP Technologies to Host Virtual 1x1 Investor Meetings at the 10th Annual East Coast IDEAS Investor Conference on June 23 & 24
NEWBURYPORT, Mass., June 22, 2020 -- UFP Technologies (Nasdaq: UFPT), an innovative designer and custom manufacturer of components, subassemblies, products, and packaging.
GlobeNewswire · 06/22 12:45
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of UFPT. Analyze the recent business situations of UFP Technologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UFPT stock price target is 55.00 with a high estimate of 55.00 and a low estimate of 55.00.
Institutional Holdings
Institutions: 136
Institutional Holdings: 6.62M
% Owned: 88.31%
Shares Outstanding: 7.49M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Commodity Chemicals
Key Executives
Chairman/Chief Executive Officer/President/Director
R. Jeffrey Bailly
Chief Financial Officer/Senior Vice President/Treasurer
Ronald Lataille
Senior Vice President/General Counsel/Director of Human Resources/Secretary
Christopher Litterio
Senior Vice President/Director of Sales/Director of Marketing
Mitchell Rock
Vice President - Research & Development
Daniel Shaw
Lead Director/Independent Director
Marc Kozin
Independent Director
Daniel Croteau
Independent Director
Cynthia Feldmann
Independent Director
Thomas Oberdorf
Independent Director
Robert Pierce
Independent Director
Lucia Quinn
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About UFPT
UFP Technologies, Inc. is a designer and custom converter of foams, plastics, composites and natural fiber materials. The Company is engaged in providing solutions to customers primarily within the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets. It converts these materials using laminating, molding, and fabricating manufacturing technologies. The Company's raw materials consist of polyethylene and polyurethane foams, sheet plastics, pulp fiber, cross-linked polyethylene and reticulated polyurethane foams, fabric and foam laminates, and natural fiber materials. The Company converts these materials to provide customers various solutions, including automotive interior trim, medical device components, disposable wound care components, military uniform and gear components, athletic padding, air filtration, high-temperature insulation, abrasive nail files and other beauty aids, and cushion packaging for their products.
Hot Stocks

Webull offers kinds of UFP Technologies, Inc. stock information, including NASDAQ:UFPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UFPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UFPT stock methods without spending real money on the virtual paper trading platform.